SFM
Sphera Funds Management Portfolio holdings
AUM
$479M
1-Year Est. Return
66.44%
This Fund
S&P 500
1 Year Est. Return
+66.44%
AUM
$422M
AUM Growth
+$39.1M
(+10%)
Holding
127
Top Buys
| 1 | +$23.6M | |
| 2 | +$13.1M | |
| 3 | +$7.57M | |
| 4 |
Cellebrite
CLBT
|
+$4.7M |
| 5 |
Varonis Systems
VRNS
|
+$4.1M |
Top Sells
| 1 | +$15.5M | |
| 2 | +$8.82M | |
| 3 | +$8.61M | |
| 4 |
Cytokinetics
CYTK
|
+$6.81M |
| 5 |
Travere Therapeutics
TVTX
|
+$6.3M |
Sector Composition
| 1 | Healthcare | 72.06% |
| 2 | Technology | 20.2% |
| 3 | Industrials | 0.82% |
| 4 | Consumer Discretionary | 0.72% |
| 5 | Communication Services | 0.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$39.4B
| $30.4M | 7.22% |
1,507,025
-113,965
|
|
||
2
Nice
NICE
$7.18B
| $22.8M | 5.41% |
+157,400
|
|
||
3
Tower Semiconductor
TSEM
$14B
| $22.5M | 5.35% |
311,802
+47,080
|
|
||
4
Nova
NVMI
$13.9B
| $14M | 3.33% |
43,896
-31,940
|
|
||
5
Invesco QQQ Trust
QQQ
$397B
| $13.8M | 3.27% |
+22,960
|
|
||
6
Biogen
BIIB
$28.2B
| $11.6M | 2.75% |
82,738
|
|
||
7
Ultragenyx Pharmaceutical
RARE
$2.26B
| $10.6M | 2.52% |
352,558
+252,473
|
|
||
8
AstraZeneca
AZN
$323B
| $10.4M | 2.46% |
135,060
|
|
||
9
Sanofi
SNY
$118B
| $10.4M | 2.46% |
219,515
|
|
||
|
10
Cytokinetics
CYTK
$7.61B
| $8.88M | 2.11% |
161,517
-165,201
|
|
||
11
Mineralys Therapeutics
MLYS
$2.32B
| $8.34M | 1.98% |
219,910
-261,064
|
|
||
12
Amicus Therapeutics
FOLD
$4.51B
| $7.81M | 1.85% |
991,142
+424
|
|
||
13
Eli Lilly
LLY
$992B
| $7.66M | 1.82% |
10,040
-1,500
|
|
||
14
Johnson & Johnson
JNJ
$599B
| $7.57M | 1.8% |
40,831
|
|
||
|
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
| $7.25M | 1.72% |
75,743
-62,258
|
|
||
16
Forte Biosciences
FBRX
$379M
| $7.11M | 1.69% |
474,309
-20,800
|
|
||
17
Syndax Pharmaceuticals
SNDX
$1.89B
| $5.97M | 1.41% |
387,716
-1,183,848
|
|
||
18
Trevi Therapeutics
TRVI
$1.53B
| $5.89M | 1.4% |
643,957
-156,000
|
|
||
19
Novo Nordisk
NVO
$166B
| $5.86M | 1.39% |
105,677
|
|
||
20
AbbVie
ABBV
$410B
| $5.85M | 1.39% |
25,256
|
|
||
|
21
Cellebrite
CLBT
$3.26B
| $5.54M | 1.31% |
+298,948
|
|
||
22
Annexon
ANNX
$835M
| $5.47M | 1.3% |
1,794,387
+30,000
|
|
||
23
Dyne Therapeutics
DYN
$2.57B
| $5.4M | 1.28% |
426,518
+205,102
|
|
||
24
Celldex Therapeutics
CLDX
$2B
| $5.37M | 1.27% |
207,764
-211,776
|
|
||
25
GSK
GSK
$119B
| $5.27M | 1.25% |
122,000
|
|